Captrust Financial Advisors Has $1.51 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Captrust Financial Advisors boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 32.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,414 shares of the biopharmaceutical company’s stock after buying an additional 1,581 shares during the quarter. Captrust Financial Advisors’ holdings in Alnylam Pharmaceuticals were worth $1,509,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Larson Financial Group LLC boosted its stake in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 73 shares in the last quarter. R Squared Ltd acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $33,000. OFI Invest Asset Management bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at $35,000. IFP Advisors Inc boosted its stake in Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 47 shares in the last quarter. Finally, Venturi Wealth Management LLC boosted its stake in Alnylam Pharmaceuticals by 6,200.0% in the fourth quarter. Venturi Wealth Management LLC now owns 252 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 248 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the transaction, the executive vice president now owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. This represents a 4.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the transaction, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. The trade was a 1.47% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,392 shares of company stock valued at $1,875,627. 1.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ALNY shares. Canaccord Genuity Group boosted their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a research note on Friday, March 21st. HC Wainwright reissued a “buy” rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Citigroup boosted their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a “buy” rating in a research note on Friday, March 21st. Chardan Capital boosted their price objective on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. Finally, Wells Fargo & Company boosted their price objective on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have assigned a buy rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $319.17.

Alnylam Pharmaceuticals Trading Down 1.2%

NASDAQ:ALNY opened at $266.86 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $144.73 and a 1-year high of $304.39. The business’s 50-day moving average price is $251.33 and its two-hundred day moving average price is $253.69. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The firm has a market capitalization of $34.80 billion, a price-to-earnings ratio of -122.98 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to analysts’ expectations of $584.32 million. During the same quarter last year, the firm earned ($0.16) earnings per share. The company’s revenue for the quarter was up 20.2% on a year-over-year basis. On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.